JP2024545135A5 - - Google Patents
Info
- Publication number
- JP2024545135A5 JP2024545135A5 JP2024534299A JP2024534299A JP2024545135A5 JP 2024545135 A5 JP2024545135 A5 JP 2024545135A5 JP 2024534299 A JP2024534299 A JP 2024534299A JP 2024534299 A JP2024534299 A JP 2024534299A JP 2024545135 A5 JP2024545135 A5 JP 2024545135A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- chloro
- amino
- carbamoyl
- fluoroacetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/136794 | 2021-12-09 | ||
| CN2021136794 | 2021-12-09 | ||
| CNPCT/CN2022/078808 | 2022-03-02 | ||
| CN2022078808 | 2022-03-02 | ||
| EP22205032.0 | 2022-11-02 | ||
| EP22205032 | 2022-11-02 | ||
| PCT/EP2022/084782 WO2023104882A1 (en) | 2021-12-09 | 2022-12-07 | Antiviral compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545135A JP2024545135A (ja) | 2024-12-05 |
| JP2024545135A5 true JP2024545135A5 (enExample) | 2025-12-15 |
Family
ID=84688511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534299A Pending JP2024545135A (ja) | 2021-12-09 | 2022-12-07 | 抗ウイルス化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250059171A1 (enExample) |
| EP (1) | EP4444711A1 (enExample) |
| JP (1) | JP2024545135A (enExample) |
| CN (1) | CN118525014A (enExample) |
| AR (1) | AR127929A1 (enExample) |
| TW (1) | TW202334113A (enExample) |
| WO (1) | WO2023104882A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022043374A1 (en) * | 2020-08-27 | 2022-03-03 | F. Hoffmann-La Roche Ag | Aminocarbamoyl compounds for the treatment of viral infections |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| EP4602050A1 (en) * | 2022-10-12 | 2025-08-20 | F. Hoffmann-La Roche AG | Antiviral compounds |
| CN118955233B (zh) * | 2024-07-27 | 2025-05-06 | 康龙化成手性医药技术(宁波)有限公司 | 一种单取代双环[1.1.1]戊烷(bcp)的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345789B2 (en) * | 2009-12-18 | 2016-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Specific inhibitors and active site probes for legumain |
| US11124497B1 (en) * | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
| WO2022212707A1 (en) * | 2021-04-01 | 2022-10-06 | Primmune Therapeutics, Inc. | Sars-3cl protease inhibitors |
-
2022
- 2022-12-07 WO PCT/EP2022/084782 patent/WO2023104882A1/en not_active Ceased
- 2022-12-07 JP JP2024534299A patent/JP2024545135A/ja active Pending
- 2022-12-07 EP EP22830839.1A patent/EP4444711A1/en active Pending
- 2022-12-07 CN CN202280080782.7A patent/CN118525014A/zh active Pending
- 2022-12-08 TW TW111147190A patent/TW202334113A/zh unknown
- 2022-12-12 AR ARP220103392A patent/AR127929A1/es unknown
-
2024
- 2024-06-06 US US18/736,151 patent/US20250059171A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667673B2 (en) | Therapeutically active compounds and their methods of use | |
| US10689414B2 (en) | Therapeutically active compounds and their methods of use | |
| US20210061822A1 (en) | Compositions and methods for inhibiting arginase activity | |
| JP4135318B2 (ja) | 新規なピリミジン−５−カルボキサミド誘導体 | |
| EP3931183B1 (en) | Compounds with ferroptosis inducing activity and methods of their use | |
| HRP20230294T1 (hr) | Modulatori tmem16a | |
| HU220866B1 (en) | Carboxamide derivatives as substituted piperazinyl-hiv protease inhibitors useful for the treatment of aids, process for producing them and pharmaceutical compositions containing them | |
| CA2648569A1 (en) | Pyridyl amide t-type calcium channel antagonists | |
| JP2024518792A5 (enExample) | ||
| SK13072002A3 (sk) | Deriváty cyklických beta-aminokyselín ako inhibítory matrixových metaloproteáz a TNF-alfa | |
| JP2000502085A (ja) | レトロウイルスプロテアーゼ阻害化合物 | |
| JP2021515004A5 (enExample) | ||
| JP2023062064A5 (enExample) | ||
| JP2022519301A5 (enExample) | ||
| JP2016516028A5 (enExample) | ||
| JP2021536505A5 (enExample) | ||
| US20250059171A1 (en) | Antiviral compounds | |
| JP2015527403A (ja) | Ｈｉｖプロテアーゼ阻害剤 | |
| JP2024511881A5 (enExample) | ||
| US12109263B2 (en) | Integrin agonists or activating compounds and methods for making and using same | |
| JP7158464B2 (ja) | カリウムチャネル阻害剤としての置換ベンゾイミダゾール | |
| CN103189364B (zh) | 二氢噁唑-2-胺衍生物 | |
| JP2022553284A5 (enExample) | ||
| JP2025505609A5 (enExample) | ||
| JP2008510017A5 (enExample) |